Andrew Balo compensation by year
DEXCOM Summary Compensation Table · all 3 fiscal years held| Component | FY2017 | FY2018 | FY2019 |
|---|---|---|---|
| Salary | $355,300 | $365,959 | $384,300 |
| Bonus | $0 | $7,500 | $7,500 |
| Stock awards | $2,250,232 | $2,317,820 | $2,146,723 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $389,054 | $461,108 | $461,160 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $22,325 | $22,251 | $23,007 |
| Total | $3,016,911 | $3,174,638 | $3,022,690 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: DEXCOM INC DEF 14A filed April 10, 2020, accession 0001093557-20-000122, and prior-year filings.
How this page was built: the DEXCOM INC filed document, accession 0001093557-20-000122. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 19,251 | $4,210,964 | — |
| RSU | 14,987 | $3,278,256 | — |
| RSU | 4,794 | $1,048,640 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in DEXCOM INC's FY2019 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2019 proxy (filed April 10, 2020)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2023-03-10 | Disposition to the issuer | — | 3,275 | $111.40 | 59,303 |
| 2023-03-10 | Disposition to the issuer | — | 2,405 | $111.40 | 56,898 |
| 2023-03-10 | Disposition to the issuer | — | 5,990 | $111.40 | 50,908 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
DEXCOM’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Kevin Sayer | Chairman, President & Chief Executive Officer | $10,279,373 |
| Quentin Blackford | Former Chief Operating Officer and Former Chief Financial Officer | $3,806,896 |
| Richard Doubleday | EVP, Chief Commercial Officer | $3,274,184 |
| Andrew Balo · this page | EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development | $3,022,690 |
| Steven Pacelli | EVP, Strategy and Corporate Development | $3,020,341 |
The full DEXCOM compensation record
free company briefThis page is one person within DEXCOM's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the DEXCOM proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are DEXCOM's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.